ArticleFuture oncology (London, England)2025
Optimizing neoadjuvant treatment in HER2-positive breast cancer: the role of HER2, HR, PD-L1 expression and regimen selection.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough neoadjuvant therapy (NAT) significantly improves the pathological complete response (pCR) rate in HER2-positive breast cancer patients, approximately 30-40% of patients remain non-responsive. Identifying predictive factors is critical for treatment optimization.
methodsWe retrospectively analyzed 179 HER2-positive breast cancer patients treated with NAT (without immunotherapy) followed by surgery at our center between August 2022 and October 2024. Clinicopathological data, treatment regimens, and pCR status were assessed. Logistic regression and ROC analysis determined independent predictors and PD-L1 cutoff.
resultsHormone receptor (HR)-negative status (OR = 2.36, 1.12-5.01), HER2 3+ (OR = 7.84, 2.34-26.31), and high PD-L1 (CPS >27.5, OR = 3.42, 1.18-9.87) independently predicted pCR. The pCR rates for the TCbHP and THP regimens were 67.4% and 60.0%, respectively, with no statistically significant difference (
conclusionHER2 3+, PD-L1 CPS > 27.5 and HR-negative are independent predictors of pCR. The TCbHP and THP regimens have comparable efficacy, and both are superior to the AC-THP regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.